Search results for "virus"
showing 10 items of 5024 documents
Hepatitis C virus co-infection and sexual risk behaviour are associated with a high homocysteine serum level in HIV-infected patients.
2012
BACKGROUND AND AIMS: A better understanding of the relationship of homocysteine with cardiovascular risk factors is needed. The objectives of this study were to assess the serum level of homocysteine in HIV-infected patients and to analyse the possible association of increased levels of the amino acid with cardiovascular risk factors, demographic and clinical characteristics of participants. METHODS: Cross-sectional study carried out as a supplementary task to the usual controls necessary in HIV-infected patients in the outpatient clinic of the Hospital General of Castellon, Spain. For two consecutive visits the demographic, clinical and HIV-related characteristics and blood analyses result…
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
2020
Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
2018
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed …
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b
2021
HCV is an important cause of hepatocellular carcinoma (HCC). HCV NS5A domain-1 interacts with cellular proteins inducing pro-oncogenic pathways. Thus, we explore genetic variations in NS5A domain-1 and their association with HCC, by analyzing 188 NS5A sequences from HCV genotype-1b infected DAA-naïve cirrhotic patients: 34 with HCC and 154 without HCC. Specific NS5A mutations significantly correlate with HCC: S3T (8.8% vs. 1.3%, p = 0.01), T122M (8.8% vs. 0.0%, p <
Modeling cost-effectiveness and health gains of a âuniversalâ versus âprioritizedâ hepatitis C virus treatment policy in a real-life cohort
2017
We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virusâinfected patients: policy 1, âuniversal,â treat all patients, regardless of fibrosis stage; policy 2, treat only âprioritizedâ patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virusâinfected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…
A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic Data
2015
The combined therapy of pegylated interferon (IFN) plus ribavirin (RBV) has been for a long time the standard treatment for patients infected with hepatitis C virus (HCV). In the case of genotype 1, only 38%–48% of patients have a positive response to the combined treatment. In previous studies, viral genetic information has been occasionally included as a predictor. Here, we consider viral genetic variation in addition to 11 clinical and 19 viral populations and evolutionary parameters to identify candidate baseline prognostic factors that could be involved in the treatment outcome. We obtained potential prognostic models for HCV subtypes la and lb in combination as well as separately. We …
Virus-nucleus interactions in late herpesvirus infection
2017
Herpes simplex virus 1 (HSV-1) on alfaherpesviruksiin kuuluva vaipallinen, kaksijuosteista DNA:ta sisältävä virus. Kosketus- ja pisaratartuntana herkästi leviävä HSV-1 on maailmanlaajuisesti huomattava taudinaiheuttaja, sillä virusta kantaa arviolta 67 % väestöstä. Tartunta on elinikäinen. Latentissa vaiheessa HSV-1:n genomi säilyy aistihermojen hermosolmukkeissa. Viruksen aktivoituminen lyyttiseen lisääntymiskiertoon oireilee tyypillisesti rakkuloina kasvojen iholla ja limakalvoilla. HSV-1:n genomin replikoituminen ja uusien viruskapsidien muodostuminen tapahtuvat isäntäsolun tumassa, jossa viruksen rakentumisalue laajenee infektion edetessä. Samalla isäntäsolun kromatiini tiivistyy ja pak…
Amber Particles as Living Plant Cell Markers in Flow Cytometry / Dzintara Daļiņas Kā Dzīvu Augu Šūnu Marķieri Plūsmas Citometrijā
2015
Abstract The unique biological properties of amber are well known. Amber particles that penetrate into the cellular matrix can potentially be used as markers of plant cell biological activity by identification of living cells in flow cytometry. However, there have been no studies on effect of amber particles on plant cells. The aim of this study was to determine effect of amber nano- and micro- (5 nm-3 μm) particles on somatic and gametic cells and to assess the possibility to use amber particles as alive plant cells markers. To reach the aim, fluorescence of cells was determined in the presence of amber particles, and amber components - spirit of amber and sodium succinate dibasic hexahydr…
Recent improvements in in situ hybridization for the detection of HPV infections in clinical samples
2020
Objective: Human Papilloma Virus (HPV) infection is well-established as a cause of cervical cancer. Importantly, early HPV detection can decrease both the frequency and mortality of HPV-related cancers. In situ hybridization (ISH) is a widely used method for the early detection of HPV. Yet, ISH can be expensive, time-consuming and, in some cases, insufficiently sensitive to detect nucleic acid target at low copy number, which may lead to false-positive or false-negative results. To address these limitations, we recently developed a novel in situ hybridization technology based on proprietary Loop RNA probes (LRPs), which provides enhanced sensitivity, high-specificity and improved cost-effec…
POTENTIAL IMPACT OF A NONAVALENT VACCINE ON HPV RELATED LOW-AND HIGH-GRADE CERVICAL INTRAEPITHELIAL LESIONS
2016
Introduction: Demonstration of the role of persistent infection, with high-risk (HR) human papillomaviruses (HPV) as the causal agent of cervical cancer made the development of first and second generation prophylactic vaccines. Bivalent and quadrivalent HPV vaccines are at the moment available in Europe. In 2014 is licensing a nonavalent HPV vaccine against HPV types: 6/11/16/18/31/33/45/52/58. The aim of our study was to evaluate the potential impact on HPV infection and related low- and high-grade cervical lesions (LSIL, HSIL) of the candidate nonavalent HPV vaccine, compared to the impact of the quadrivalent, in a female population living in Sicily. Materials and Methods: HPV genotypes w…